Search results for "Lymphatic"

showing 9 items of 1179 documents

297: Establishment of a chimeric NOD-scid/IL2RγcNull transplantation-model to evaluate graft-vs-host and graft-vs-leukemia immune responses of ex viv…

2007

musculoskeletal diseasesTransplantationbusiness.industryHost (biology)NodT lymphocyteHematologymedicine.diseaseVirologyTransplantationstomatognathic diseasesLeukemiaImmune systemimmune system diseaseshemic and lymphatic diseasesImmunologyMedicinebusinessEx vivoBiology of Blood and Marrow Transplantation
researchProduct

Hla-Bb,Dr3 Phenotype and the Antibody Response Against Epstein-Barr Virus

1993

Antibodies against the viral capsid antigen (VCA) and nuclear antigens (EBNAs) of the Epstein-Barr virus (EBV) were determined in a sample of Sicilian population. A significant correlation was observed between HLA-BB,DR3 phenotype and reduced titres of antibodies to EBNAs, whereas HLA-BB,DR3 positive individuals displayed levels of antibodies to VCA comparable to those of HLA-BB,DR3 negative ones. These results further strenghten the suggestion that HLA-BB,DR3 positive subjects are low responders and that the depth of immune response depends on on the fashion of antigenic challenge.

musculoskeletal diseaseseducation.field_of_studyvirusesImmunologyPopulationGeneral MedicineBiologymedicine.disease_causeVirologyEpstein–Barr virusHerpesviridaeVirusSerologyAntigenimmune system diseaseshemic and lymphatic diseasesImmunologyHumoral immunitymedicinebiology.proteinAntibodyeducationImmunological Investigations
researchProduct

MDS-191: Long-Term Efficacy and Safety of Luspatercept in Lower-Risk Myelodysplastic Syndromes (MDS): Phase 2 PACE-MDS Study

2020

Background: Luspatercept, a first-in-class erythroid maturation agent, has been investigated in patients with LR-MDS and ring sideroblasts (RS) (MEDALIST; Fenaux and Platzbecker NEJM 2020) and in an ongoing Phase 3 trial regardless of RS status (COMMANDS, NCT03682536 ). The previously reported Phase 2 trial of luspatercept (Platzbecker Lanc Onc 2017) includes subtypes of LR-MDS with and without RS, regardless of prior ESA exposure, and various EPO levels. Aims: Evaluate the long-term safety and efficacy of luspatercept in LR-MDS. Methods: Patients were IPSS low/int-1, age ≥ 18 years, Hgb NCT01749514 ; NCT02268383 ). Results: As of 13July2019, 115 patients were enrolled, of whom 108 were tre…

myalgiaCancer Researchmedicine.medical_specialtyErythemabusiness.industryMyelodysplastic syndromesPeripheral edemaPhases of clinical researchHematologymedicine.diseaseLower riskClinical trialOncologyhemic and lymphatic diseasesInternal medicinemedicinemedicine.symptomBone painbusinessClinical Lymphoma Myeloma and Leukemia
researchProduct

Photoluminescent Detection of Human T-Lymphoblastic Cells by ZnO Nanorods.

2020

The precise detection of cancer cells currently remains a global challenge. One-dimensional (1D) semiconductor nanostructures (e.g., ZnO nanorods) have attracted attention due to their potential use in cancer biosensors. In the current study, it was demonstrated that the possibility of a photoluminescent detection of human leukemic T-cells by using a zinc oxide nanorods (ZnO NRs) platform. Monoclonal antibodies (MABs) anti-CD5 against a cluster of differentiation (CD) proteins on the pathologic cell surface have been used as a bioselective layer on the ZnO surface. The optimal concentration of the protein anti-CD5 to form an effective bioselective layer on the ZnO NRs surface was selected. …

room temperature photoluminescenceT-LymphocytesPharmaceutical Science02 engineering and technologyBiosensing TechniquesT-lymphoblasts detection01 natural sciencesAnalytical Chemistryhemic and lymphatic diseasesDrug Discoveryeducation.field_of_studyNanotubesmedicine.diagnostic_testAntibodies MonoclonalPrecursor Cell Lymphoblastic Leukemia-Lymphoma021001 nanoscience & nanotechnologyFlow CytometryChemistry (miscellaneous)Molecular MedicineNanorodZinc Oxide0210 nano-technologymonoclonal antibody anti-CD5PhotoluminescenceMaterials sciencePopulationchemistry.chemical_elementNanotechnologyZincCD5 AntigensArticleFlow cytometrylcsh:QD241-441Adsorptionlcsh:Organic chemistryCell Line TumormedicineHumansPhysical and Theoretical ChemistryeducationMOLT-4 cell linecluster of differentiation proteins010401 analytical chemistryOrganic Chemistry0104 chemical sciencesNanostructureschemistryCancer cellLuminescent MeasurementsGlassBiosensorzinc oxide nanorodsMolecules (Basel, Switzerland)
researchProduct

Epstein-Barr virus in oral proliferative verrucous leukoplakia and squamous cell carcinoma : a preliminary study

2008

The aim of this study was to analyze proliferative verrucous leukoplakia (PVL) and oral squamous cell carcinoma (OSCC) for the possible presence of Epstein-Barr virus (EBV). We studied three groups: Sub-Group 1 was composed of 10 patients with PVL, (6 of whom had developed OSCC); Sub-Group 2 comprised 5 patients with OSCC but no preceding PVL; and Sub-Group 3 were 5 controls with clinically normal oral mucosa. Oral biopsies from all cases were examined for Epstein-Barr virus (EBV) by nested PCR. EBV was detected in 60% of Sub-Group 1 patients (PVL ) and in 40% of Sub-Group 2 (OSCC), but in 0% of SubGroup 3 (controls).

stomatognathic diseaseshemic and lymphatic diseasesUNESCO::CIENCIAS MÉDICAS:CIENCIAS MÉDICAS [UNESCO]
researchProduct

Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myelo…

2022

Dataset used for the study "Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia"

surgical procedures operativehemic and lymphatic diseases
researchProduct

Vascularized lymph node transfer for treatment of extremity lymphedema: An overview of current controversies regarding donor sites, recipient sites a…

2018

As lymphatic microsurgery has become more common, vascularized lymph node transfer ascended to the forefront in many centers for the surgical management of advanced stages of lymphedema showing substantial clinical improvement. However, no consensus has been reached among experts regarding many details of the procedures, including patient selection criteria, type of treatment, donor, and recipient sites and postoperative evaluation of the outcome. Here, we will review these issues and provide the current results of this procedure.

vascularized lymph node transfer lymphedema lymphatic microsurgerymedicine.medical_specialtymedicine.medical_treatmentTreatment outcome030230 surgery03 medical and health sciences0302 clinical medicinemedicineHumansLymphedemaLymph nodebusiness.industryGeneral surgeryAdvanced stageExtremitiesGeneral MedicineMicrosurgerymedicine.diseaselymphatic microsurgery; lymphedema; vascularized lymph node transfer; Humans; Lymph Nodes; Lymphedema; Treatment Outcome; ExtremitiesLymphatic systemLymphedemamedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisSurgeryLymph NodesbusinessJournal of surgical oncology
researchProduct

Intratympanic gentamicin: a one day protocol treatment for unilateral Meniere’s disease.

2007

Purpose: The objective of this study was to assess the usefulness of low-dose intratympanic gentamicin administration in patients with Meniere’s disease (MD). Materials and Methods: We carried out a retrospective review of the charts of 55 patients with definite MD in accordance with the AAO-HNS (American Academy of Otolaryngology–Head and Neck Surgery) Diagnostic Scale who were treated at Gruppo Otologico (Piacenza, Rome, Italy). The treatment protocol consisted of 3 intratympanic injections of gentamicin at a 12-hour interval between each administration. Results: Results were resumed in accordance with AAO-HNS criteria and showed complete control of vertigo spells in 60% (class A), good c…

vertigoIntratympanic gentamicinEndolymphatic hydropsgentamicinMeniere’s disease
researchProduct

Tumor targeting of baculovirus displaying a lymphatic homing peptide.

2008

Background Tumor-associated cells and vasculature express attractive molecular markers for site-specific vector targeting. To attain tumor-selective tropism, we recently developed a baculovirus vector displaying the lymphatic homing peptide LyP-1, originally identified by ex vivo/in vivo screening of phage display libraries, on the viral envelope by fusion to the transmembrane anchor of vesicular stomatitis virus G-protein. Methods In the present study, we explored the specificity and kinetics of viral binding and internalization as well as in vivo tumor homing of the LyP-1 displaying virus to elucidate the applicability of baculovirus for targeted therapies. Results We demonstrated that th…

virusesmedia_common.quotation_subjectGenetic VectorsMice NudeBiologyPeptides CyclicVirus03 medical and health sciencesTransduction (genetics)Mice0302 clinical medicineViral envelopeViral Envelope ProteinsIn vivoTransduction GeneticCell Line TumorNeoplasmsDrug DiscoveryGeneticsAnimalsHumansTransgenesInternalizationMolecular BiologyGenetics (clinical)030304 developmental biologymedia_commonLymphatic Vessels0303 health sciencesBinding SitesMembrane GlycoproteinsGene Transfer TechniquesGenetic Therapybiology.organism_classificationMolecular biology3. Good healthCell biologyVesicular stomatitis virus030220 oncology & carcinogenesisMolecular MedicineBaculoviridaeEx vivoHoming (hematopoietic)The journal of gene medicine
researchProduct